Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2008Hypertension ResearchOpen Access

Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation

View Full Paper
Ask AI
Bookmark
Share

Key result

Atorvastatin significantly reduced the heart/body weight ratio from 8.69 mg/g to 6.45 mg/g (p<0.001) in mice with pressure overload, ameliorating cardiac remodeling.

Why the study?

Does atorvastatin improve cardiac remodeling in mice with pressure overload?

Population

Male C57BL/6J mice with transverse aortic constriction (TAC) and cultured neonatal rat cardiomyocytes

Comparison

Atorvastatin (5 mg/kg/day) orally administered vs Vehicle

Design

Preclinical

Follow-up

4 weeks

Authors

YLYulin LiaoHZHui ZhaoAOAkiko Ogai

Discussion

Loading...

Member takes

Overview

Atorvastatin attenuated remodeling via EGFR in TAC mice; leaves open human translation and requires clinical trials.

Structured PICO

Does atorvastatin improve cardiac remodeling in mice with pressure overload?

P
Population
46 male C57BL/6J mice (7-8 weeks old) subjected to transverse aortic constriction to induce cardiac hypertrophy, followed for 4 weeks.
I
Intervention
Atorvastatin (5 mg/kg/day) orally administered
C
Comparator
Vehicle
O
Outcome
Cardiac remodeling parameters including heart/body weight ratio, lung/body weight ratio, and EGFR activationsurrogate

Main Result

Absolute Event Rate: 6.45% vs 8.69%

p-value: p=<0.001

Atorvastatin ameliorates cardiac remodeling in mice with pressure overload, likely via inhibition of the EGFR signaling pathway.

Limitations

  • Animal model results may not fully translate to human clinical heart failure
  • Other pleiotropic actions of atorvastatin (antioxidant, anti-inflammatory, nitric oxide enhancement) might have contributed to the inhibitory effect on cardiac remodeling

Cite This Study

Liao et al. (2008) studied Cardiac remodeling with pressure overload (n=46). Atorvastatin vs. Vehicle was evaluated on Heart/body weight ratio (p=<0.001). Atorvastatin significantly reduced the heart/body weight ratio from 8.69 mg/g to 6.45 mg/g (p<0.001) in mice with pressure overload, ameliorating cardiac remodeling.

synapsesocial.com/papers/6a5da298a59a9c8bb700ffe9https://doi.org/10.1291/hypres.31.335
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Atorvastatin Attenuates Myocardial Hypertrophy in Spontaneously Hypertensive Rats via the C/EBPβ/PGC-1α/UCP3 Pathway2018 · 17 citations
  2. 2Prevention of Cardiac Hypertrophy by Atorvastatin in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy2005 · 160 citations
  3. 3Atorvastatin Prevents Left Ventricular Remodeling in Spontaneously Hypertensive Rats2010 · 8 citations
  4. 4Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways2018 · 27 citations
  5. 5Effect of Atorvastatin on Expression of Peroxisome Proliferator-activated Receptor Beta/delta in Angiotensin II-induced Hypertrophic Myocardial Cells In Vitro2015 · 5 citations